Parental cell line | RRID | Origin | Therapy drug | Parental IC50 | Therapy target | Exposure period | Resistant cell line | Resistant IC50 | EMT | Ref |
---|---|---|---|---|---|---|---|---|---|---|
HepG2 (n = 2) | CVCL_0027 | Liver | Sorafenib | 0.28 μM | VEGFR, PDGFR, Raf kinases | 6–12 months | HepG2S1 | 0.44 μM | Full | [16] |
HepG2S3 | 0.69 μM | Full | ||||||||
HCC4006P1 | CVCL_1269 | Lung | Erlotinib | 0.03 μM | EGFR | 3–6 months | HCC4006ER | 0.97 μM | Full | [17] |
Panc 03.27 (‘PancVB’) (n = 2) | CVCL_1635 | Pancreas | 5-Fluorouracil | 14.63 μM | Thymidylate synthase | 6 months | PancB1Q | 55.72 μM | Full | [18] |
PancB1V | 30.75 μM | Full | ||||||||
HCC4006P2 | CVCL_1269 | Lung | Gefitinib | 0.10 μM | EGFR | 3 months | HCC4006GR | 0.59 μM | Full | [19] |
HCC827P | CVCL_2063 | Lung | Gefitinib | 0.027 μM | EGFR | 3 months | HCC827GR | 0.046 μM | Full | |
UWB 1.289 (n = 2) | CVCL_B079 | Ovary | Olaparib | 58.02 μM | PARP | 5 months | U10 | 512.33 μM | Partial | [20] |
U100 | 699.41 μM | Partial | ||||||||
IGROV-1 | CVCL_1304 | Ovary | Cisplatin | 64.04 μM | DNA replication | 9 months | IGROV-1/CDDP | 388.02 μM | Partial | [21] |